Treatment of Acute Myocarditis in Cardiac Sarcoidosis

Acute myocarditis occurring in the setting of cardiac sarcoidosis is a distinct clinical scenario that warrants a specific treatment approach tailored to this underlying condition.

Clinical Scenario

This protocol addresses acute myocarditis in patients with cardiac sarcoidosis. The co-existence of these diagnoses defines both the patient population and the treatment strategy applied.

Treatment Approach

Management in this setting involves targeted monoclonal antibody therapy. The structured protocol specifies which agents are indicated and how treatment is organised — access the full regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/ehaf192

Cardiac sarcoidosis
Infliximabj or adalimumabk, rituximabi
Infliximab (monoclonal antibody against TNF-α): 5 mg/kg i.v. at weeks 0, 2, 6, then every ∼8 weeks (maintenance).
Adalimumab (anti-TNF-α fully human monoclonal antibody) 40 mg SC every week (or every 2 weeks, per clinical response).
Rituximab (monoclonal antibody against CD20 on B cells): 375 mg/m² i.v. weekly × 4 doses (1 month).

View source ↗